{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:42:14Z","timestamp":1791906134698,"version":"4.3.4"},"reference-count":42,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,4,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chronic myelomonocytic leukemia (CMML) constitutes a hematopoietic stem cell (HSC) disorder characterized by prominent monocytosis and myelodysplasia. Although genome sequencing has revealed the CMML mutation profile, the mechanism of disease development remains unclear. Here we show that aberrant histone acetylation by nucleoporin-98 (NUP98)-HBO1, a newly identified fusion in a patient with CMML, is sufficient to generate clinically relevant CMML pathogenesis. Overexpression of NUP98-HBO1 in murine HSC\/progenitors (HSC\/Ps) induced diverse CMML phenotypes, such as severe leukocytosis, increased CD115+ Ly6Chigh monocytes (an equivalent subpopulation to human classical CD14+ CD16\u2212 monocytes), macrocytic anemia, thrombocytopenia, megakaryocyte-lineage dysplasia, splenomegaly, and cachexia. A NUP98-HBO1\u2013mediated transcriptional signature in human CD34+ cells was specifically activated in HSC\/Ps from a CMML patient cohort. Besides critical determinants of monocytic cell fate choice in HSC\/Ps, an oncogenic HOXA9 signature was significantly activated by NUP98-HBO1 fusion through aberrant histone acetylation. Increased HOXA9 gene expression level with disease progression was confirmed in our CMML cohort. Genetic disruption of NUP98-HBO1 histone acetyltransferase activity abrogated its leukemogenic potential and disease development in human cells and a mouse model. Furthermore, treatment of azacytidine was effective in our CMML mice. The recapitulation of CMML clinical phenotypes and gene expression profile by the HBO1 fusion suggests our new model as a useful platform for elucidating the central downstream mediators underlying diverse CMML-related mutations and testing multiple compounds, providing novel therapeutic potential.<\/jats:p>","DOI":"10.1182\/bloodadvances.2018025007","type":"journal-article","created":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T17:55:15Z","timestamp":1554314115000},"page":"1047-1060","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":29,"title":["NUP98-HBO1\u2013fusion generates phenotypically and genetically relevant chronic myelomonocytic leukemia pathogenesis"],"prefix":"10.1182","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1490-9923","authenticated-orcid":false,"given":"Yoshihiro","family":"Hayashi","sequence":"first","affiliation":[{"name":"Laboratory of Oncology, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Harada","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Medicine, Bunkyo Gakuin University, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kagiyama","sequence":"additional","affiliation":[{"name":"Laboratory of Oncology, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayuri","family":"Nishikawa","sequence":"additional","affiliation":[{"name":"Laboratory of Oncology, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Ding","sequence":"additional","affiliation":[{"name":"Division of Oncology and Hematology, Edogawa Hospital, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Imagawa","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Shingai","sequence":"additional","affiliation":[{"name":"Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Kato","sequence":"additional","affiliation":[{"name":"Division of Cellular Therapy, Institute of Medical Science, University of Tokyo, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiro","family":"Kitaura","sequence":"additional","affiliation":[{"name":"Atopy Research Center, Juntendo University Graduate School of Medicine, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Hokaiwado","sequence":"additional","affiliation":[{"name":"Laboratory of Oncology, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Maemoto","sequence":"additional","affiliation":[{"name":"Laboratory of Cell Signaling, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Ito","sequence":"additional","affiliation":[{"name":"Laboratory of Cell Signaling, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Matsui","sequence":"additional","affiliation":[{"name":"Department of Molecular Laboratory Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issay","family":"Kitabayashi","sequence":"additional","affiliation":[{"name":"Division of Hematological Malignancy, National Cancer Center Research Institute, Tokyo, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Iwama","sequence":"additional","affiliation":[{"name":"Department of Cellular and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, University of Tokyo, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Komatsu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Kitamura","sequence":"additional","affiliation":[{"name":"Division of Cellular Therapy, Institute of Medical Science, University of Tokyo, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Harada","sequence":"additional","affiliation":[{"name":"Laboratory of Oncology, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,4,3]]},"reference":[{"issue":"7","key":"2020021108281221300_B1","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/leu.2013.100","article-title":"An evolutionary perspective on chronic myelomonocytic leukemia","volume":"27","author":"Itzykson","year":"2013","journal-title":"Leukemia"},{"issue":"3","key":"2020021108281221300_B2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/bjh.12756","article-title":"Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review","volume":"165","author":"Patnaik","year":"2014","journal-title":"Br J Haematol"},{"issue":"2","key":"2020021108281221300_B3","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1038\/bcj.2016.5","article-title":"Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia","volume":"6","author":"Patnaik","year":"2016","journal-title":"Blood Cancer J"},{"issue":"2","key":"2020021108281221300_B4","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1182\/blood-2017-04-736421","article-title":"How I treat chronic myelomonocytic leukemia","volume":"130","author":"Solary","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2020021108281221300_B5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2011.06.001","article-title":"Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation","volume":"20","author":"Moran-Crusio","year":"2011","journal-title":"Cancer Cell"},{"issue":"11","key":"2020021108281221300_B6","doi-asserted-by":"crossref","first-page":"4627","DOI":"10.1172\/JCI70739","article-title":"Myelodysplastic syndromes are induced by histone methylation\u2013altering ASXL1 mutations","volume":"123","author":"Inoue","year":"2013","journal-title":"J Clin Invest"},{"issue":"5","key":"2020021108281221300_B7","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ccell.2015.04.006","article-title":"SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition","volume":"27","author":"Kim","year":"2015","journal-title":"Cancer Cell"},{"issue":"15","key":"2020021108281221300_B8","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1182\/blood-2016-06-724658","article-title":"Acquired expression of Cbl Q367P in mice induces dysplastic myelopoiesis mimicking chronic myelomonocytic leukemia","volume":"129","author":"Nakata","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2020021108281221300_B9","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ccell.2017.11.012","article-title":"Cooperative epigenetic remodeling by TET2 loss and NRAS mutation drives myeloid transformation and MEK inhibitor sensitivity","volume":"33","author":"Kunimoto","year":"2018","journal-title":"Cancer Cell"},{"issue":"37","key":"2020021108281221300_B10","doi-asserted-by":"crossref","first-page":"5395","DOI":"10.1038\/sj.onc.1210608","article-title":"The MYST family of histone acetyltransferases and their intimate links to cancer","volume":"26","author":"Avvakumov","year":"2007","journal-title":"Oncogene"},{"issue":"19","key":"2020021108281221300_B11","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1101\/gad.1674108","article-title":"HBO1 histone acetylase is a coactivator of the replication licensing factor Cdt1","volume":"22","author":"Miotto","year":"2008","journal-title":"Genes Dev"},{"issue":"3","key":"2020021108281221300_B12","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/MCB.06455-11","article-title":"Conserved molecular interactions within the HBO1 acetyltransferase complexes regulate cell proliferation","volume":"32","author":"Avvakumov","year":"2012","journal-title":"Mol Cell Biol"},{"issue":"7","key":"2020021108281221300_B13","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1128\/MCB.00572-17","article-title":"UV damage-induced phosphorylation of HBO1 triggers CRL4DDB2-mediated degradation to regulate cell proliferation [published correction appears in","volume":"38","author":"Matsunuma","year":"2018","journal-title":"Mol Cell Biol"},{"issue":"1","key":"2020021108281221300_B14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/ng0996-33","article-title":"The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein","volume":"14","author":"Borrow","year":"1996","journal-title":"Nat Genet"},{"issue":"24","key":"2020021108281221300_B15","doi-asserted-by":"crossref","first-page":"7184","DOI":"10.1093\/emboj\/20.24.7184","article-title":"Activation of AML1-mediated transcription by MOZ and inhibition by the MOZ-CBP fusion protein","volume":"20","author":"Kitabayashi","year":"2001","journal-title":"EMBO J"},{"issue":"4","key":"2020021108281221300_B16","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/hmg\/10.4.395","article-title":"Fusion of the MORF and CBP genes in acute myeloid leukemia with the t(10;16)(q22;p13)","volume":"10","author":"Panagopoulos","year":"2001","journal-title":"Hum Mol Genet"},{"issue":"3","key":"2020021108281221300_B17","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S1535-6108(03)00051-5","article-title":"MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP","volume":"3","author":"Deguchi","year":"2003","journal-title":"Cancer Cell"},{"issue":"1-2","key":"2020021108281221300_B18","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.gene.2009.01.020","article-title":"Histone acetyltransferase Hbo1: catalytic activity, cellular abundance, and links to primary cancers","volume":"436","author":"Iizuka","year":"2009","journal-title":"Gene"},{"issue":"8","key":"2020021108281221300_B19","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1182\/blood-2007-01-068346","article-title":"AML1 mutations induced MDS and MDS\/AML in a mouse BMT model","volume":"111","author":"Watanabe-Okochi","year":"2008","journal-title":"Blood"},{"issue":"43","key":"2020021108281221300_B20","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"17","key":"2020021108281221300_B21","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1182\/blood-2012-06-434423","article-title":"RUNX1\/AML1 mutant collaborates with BMI1 overexpression in the development of human and murine myelodysplastic syndromes","volume":"121","author":"Harada","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2020021108281221300_B22","doi-asserted-by":"crossref","first-page":"e0152321","DOI":"10.1371\/journal.pone.0152321","article-title":"Expression of leukemia-associated Nup98 fusion proteins generates an aberrant nuclear envelope phenotype","volume":"11","author":"Fahrenkrog","year":"2016","journal-title":"PLoS One"},{"issue":"23","key":"2020021108281221300_B23","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1182\/blood-2015-01-620781","article-title":"Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia","volume":"125","author":"Selimoglu-Buet","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2020021108281221300_B24","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/leu.2010.31","article-title":"Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells","volume":"24","author":"Pellagatti","year":"2010","journal-title":"Leukemia"},{"key":"2020021108281221300_B25","doi-asserted-by":"crossref","first-page":"e00825","DOI":"10.7554\/eLife.00825","article-title":"MYBL2 is a sub-haploinsufficient tumor suppressor gene in myeloid malignancy","volume":"2","author":"Heinrichs","year":"2013","journal-title":"eLife"},{"issue":"7622","key":"2020021108281221300_B26","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/nature19348","article-title":"Single-cell analysis of mixed-lineage states leading to a binary cell fate choice","volume":"537","author":"Olsson","year":"2016","journal-title":"Nature"},{"issue":"11","key":"2020021108281221300_B27","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2007-09-113597","article-title":"HOXA9 is required for survival in human MLL-rearranged acute leukemias","volume":"113","author":"Faber","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2020021108281221300_B28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.molcel.2005.12.007","article-title":"ING tumor suppressor proteins are critical regulators of chromatin acetylation required for genome expression and perpetuation","volume":"21","author":"Doyon","year":"2006","journal-title":"Mol Cell"},{"issue":"43","key":"2020021108281221300_B29","doi-asserted-by":"crossref","first-page":"28817","DOI":"10.1074\/jbc.M801407200","article-title":"Role of Jade-1 in the histone acetyltransferase (HAT) HBO1 complex","volume":"283","author":"Foy","year":"2008","journal-title":"J Biol Chem"},{"issue":"1","key":"2020021108281221300_B30","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.molcel.2009.12.012","article-title":"HBO1 histone acetylase activity is essential for DNA replication licensing and inhibited by Geminin","volume":"37","author":"Miotto","year":"2010","journal-title":"Mol Cell"},{"issue":"9","key":"2020021108281221300_B31","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1182\/blood-2011-01-331892","article-title":"The Hbo1-Brd1\/Brpf2 complex is responsible for global acetylation of H3K14 and required for fetal liver erythropoiesis","volume":"118","author":"Mishima","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2020021108281221300_B32","doi-asserted-by":"crossref","first-page":"5872","DOI":"10.1038\/ncomms6872","article-title":"Histone acetylation mediated by Brd1 is crucial for Cd8 gene activation during early thymocyte development","volume":"5","author":"Mishima","year":"2014","journal-title":"Nat Commun"},{"issue":"2","key":"2020021108281221300_B33","doi-asserted-by":"crossref","first-page":"176","DOI":"10.15252\/embj.201591293","article-title":"BRPF3-HBO1 regulates replication origin activation and histone H3K14 acetylation","volume":"35","author":"Feng","year":"2016","journal-title":"EMBO J"},{"issue":"5","key":"2020021108281221300_B34","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1200\/JCO.2010.31.0854","article-title":"Hypomethylating agents and other novel strategies in myelodysplastic syndromes","volume":"29","author":"Garcia-Manero","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"2020021108281221300_B35","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12964-017-0168-z","article-title":"The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation","volume":"15","author":"Wolff","year":"2017","journal-title":"Cell Commun Signal"},{"issue":"1","key":"2020021108281221300_B36","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1038\/ncomms5177","article-title":"Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation","volume":"5","author":"Sashida","year":"2014","journal-title":"Nat Commun"},{"issue":"3","key":"2020021108281221300_B37","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/stem.140281","article-title":"The role of HOX homeobox genes in normal and leukemic hematopoiesis","volume":"14","author":"Lawrence","year":"1996","journal-title":"Stem Cells"},{"issue":"2","key":"2020021108281221300_B38","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ccr.2012.06.032","article-title":"ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression","volume":"22","author":"Abdel-Wahab","year":"2012","journal-title":"Cancer Cell"},{"issue":"25","key":"2020021108281221300_B39","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1182\/blood-2012-10-460170","article-title":"GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia","volume":"121","author":"Padron","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2020021108281221300_B40","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2009.23.4781","article-title":"DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes","volume":"28","author":"Shen","year":"2010","journal-title":"J Clin Oncol"},{"issue":"16","key":"2020021108281221300_B41","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1182\/blood-2009-01-200519","article-title":"MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation","volume":"114","author":"Figueroa","year":"2009","journal-title":"Blood"},{"issue":"5","key":"2020021108281221300_B42","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.cell.2015.07.056","article-title":"DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts","volume":"162","author":"Roulois","year":"2015","journal-title":"Cell"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/7\/1047\/1631564\/advances025007.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/7\/1047\/1631564\/advances025007.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T08:47:21Z","timestamp":1581410841000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/7\/1047\/247282\/NUP98HBO1fusion-generates-phenotypically-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,3]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,4,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2018025007","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,3]]}}}